Mansoor Raza Mirza, MD, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.
Mansoor Raza Mirza, MD, medical director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit and chief oncologist within the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the clinical implications of the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.
During the 2020 ASCO Virtual Scientific Program, final analysis of the trial demonstrated continued, statistically significant activity with the combination of niraparib (Zejula) and bevacizumab (Avastin) compared with niraparib alone in patients with platinum-sensitive relapsed ovarian cancer.
Previous findings from the study served as the basis for the combination’s inclusion in the National Comprehensive Cancer Network guidelines as a potential option for this patient population, Mirza explains.
Currently, some countries are prioritizing this regimen for their patients over previously established standard of care options, Mirza says.
However, in his opinion, level 1 evidence from a phase 3 trial comparing niraparib/bevacizumab with standard of care therapy is needed to establish the combination as a preferred regimen in this space, Mirza concludes.